G6PD缺陷症之中藥使用安全性

The safety of traditional Chinese medicine for G6PD deficiency

黃湘淇(Siang-Ci Huang)；賴尚志(Shang-Chih Lai)

G6PD缺陷症 ； 中藥 ； 溶血 ； G6PD deficiency ； Traditional Chinese medicine ； Hemolysis

北台灣中醫醫學雜誌

15卷2期（2023 / 09 / 30）

29 - 58

繁體中文;英文

本文之目的為探討G6PD缺陷症病患使用中藥之安全性，我們使用資料庫（Pubmed、中國期刊全文數據庫、WANGFANG Database、華藝線上圖書館）來搜尋相關文獻，總共37篇文獻被納入。在結果的部分我們分成正、反面來整理，正面的結果為中藥對於G6PD缺陷症的病患具有保護作用，或是中藥對於紅血球具有抗氧化作用。至於反面的結果為中藥會造成G6PD缺陷症的病患之溶血，或是中藥對於紅血球會產生溶血作用。分析結果發現正面結果之文獻共20篇，反面結果之文獻共16篇，另外有一篇文獻為綜合性評論，不特別列於正面或反面文獻。根據搜尋到的文獻，即使有些中藥曾被指出可能具有溶血風險，但目前仍沒有足夠證據指出G6PD缺陷症患者需禁用這些中藥，但因存在正反面意見，且相關安全性研究仍較不足，因此我們認為G6PD缺陷症患者仍應審慎使用，我們將這些中藥進行風險分類，並提出建議，期望提供臨床醫師與醫護人員參考。

The purpose of this study was to investigate the safety of using traditional Chinese medicine in individuals with G6PD deficiency. We collected the literatures from Pubmed, China National Knowledge Infrastructure (CNKI), WANGFANG Database, and Airiti Library (including CEPS and CETD), and 37 literatures were included in our study. In the section of results, we categorized the findings into positive and negative aspects. Positive results indicate that traditional Chinese medicine have a protective effect on individuals with G6PD deficiency or possess antioxidant effect on red blood cells. On the other hand, negative results suggest that traditional Chinese medicine may lead to hemolysis in individuals with G6PD deficiency or have a hemolytic effect on red blood cells. Our analysis revealed 20 literatures with positive results, 16 literatures with negative results, and one comprehensive review that was not specifically categorized as positive or negative. Based on our results, although some traditional Chinese medicine had a risk of hemolysis, there is currently insufficient evidence to conclusively recommend the prohibition of these medicines for individuals with G6PD deficiency. However, because of the existence of conflicting opinions and a lack of comprehensive studies about safety, we recommend that individuals with G6PD deficiency use these traditional Chinese medicines cautiously. We categorized these medicine based on their risk and provided recommendations, with the hope of offering guidance to clinical practitioners and healthcare professionals.